Prevention of experimental Haemophilus ducreyi infection: A randomized, controlled clinical trial

Alice C. Thornton, Edward M. O'Mara, Suellyn J. Sorensen, Thomas J. Hiltke, Kate Fortney, Barry Katz, Ronald E. Shoup, Antoinette F. Hood, Stanley M. Spinola

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


Human subjects were infected with Haemophilus ducreyi. All subjects developed papules and were randomized to treatment with a single dose of azithromycin (1 g) or ciprofloxacin (500 mg). At weekly intervals, volunteers were reinoculated with H. ducreyi, and drug concentrations were measured in peripheral blood mononuclear cells (PBMC). When papules developed, the subjects were treated with antibiotics and dismissed from the study. Eight of the ciprofloxacin-treated subjects developed papules 1 week after the initial treatment, and the ninth subject developed disease 2 weeks after treatment. The 9 azithromycin-treated subjects developed papules 4-10 weeks (mean, 6.8) after the initial treatment (P < .001). Azithromycin was detected in PBMC for 3-6 weeks (mean, 4). Pre- and posttreatment lesions had histology typical of experimental chancroid or were culture positive. Azithromycin prevents experimental chancroid for nearly 2 months. These findings have implications for strategies to prevent chancroid.

Original languageEnglish (US)
Pages (from-to)1608-1613
Number of pages6
JournalJournal of Infectious Diseases
Issue number6
StatePublished - 1998

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Prevention of experimental Haemophilus ducreyi infection: A randomized, controlled clinical trial'. Together they form a unique fingerprint.

Cite this